Cecilia Chung

Dr. Cecilia Chung


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
CCCecilia Chung
Cecilia Chung
IAIngrid Avalos
Ingrid Avalos
AOAnnette Oeser
Annette Oeser
TGTebeb Gebretsadik
Tebeb Gebretsadik
ASAyumi Shintani
Ayumi Shintani
CSC Michael Stein
C Michael Stein
Background: The metabolic syndrome is an independent risk factor for ischaemic heart disease. Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis; however, there are no controlled studies of the metabolic syndrome in patients with SLE. Objective: To compare the prevalence of the metabolic syndrome in patients with SLE and controls and to evaluate its relationship to other cardiovascular risk factors and inflammation. Methods: 102 patients with SLE and 101 controls were studied. The prevalence of the metabolic syndrome was compared in patients and controls using the National Cholesterol Education Program Adult Treatment Panel III (NCEP) and the World Health Organization (WHO) definitions, and associations with cardiovascular risk factors and lupus characteristics were examined. Results: The metabolic syndrome was present in 32.4% of patients and in 10.9% of controls subjects (p<0.001) using the WHO definition that requires direct determination of insulin resistance, and in 29.4% of patients with SLE and in 19.8% of controls (p = 0.14) using the NCEP definition. Among patients with SLE, both definitions were significantly associated with higher concentrations of C reactive protein (p = 0.001) and the NCEP definition was significantly associated with higher concentrations of homocysteine (p<0.001), lipoprotein (a) (p = 0.02) and cholesterol (p = 0.04). Neither lupus disease activity nor damage scores were associated with the metabolic syndrome. Conclusions: Patients with SLE have a higher prevalence of insulin resistance and consequently of the WHO-defined metabolic syndrome than controls. In patients with SLE, the metabolic syndrome was associated with higher levels of inflammation and may provide a link between inflammation and increased cardiovascular risk.

1 December 2013 in Vaccine
Verified
Journal Article
Closed access
CCCecilia Chung
Cecilia Chung
PRPatricia Rohan
Patricia Rohan
SKShanthi Krishnaswami
Shanthi Krishnaswami
MMMelissa L. McPheeters
Melissa L. McPheeters

1 August 2018 in Pediatrics
Verified
Journal Article
Open access
PDF file
CCCecilia Chung
Cecilia Chung
SCS. Todd Callahan
S. Todd Callahan
WCWilliam O. Cooper
William O. Cooper
WDWilliam D. Dupont
William D. Dupont
KMKatherine T. Murray
Katherine T. Murray
WRWayne A. Ray
Wayne A. Ray
BACKGROUND AND OBJECTIVES: Little is known about opioid prescribing for children without severe conditions. We studied the prevalence of and indications for outpatient opioid prescriptions and the incidence of opioid-related adverse events in this population. METHODS: This retrospective cohort study between 1999 and 2014 included Tennessee Medicaid children and adolescents aged 2 to 17 without major chronic diseases, prolonged hospitalization, institutional residence, or evidence of a substance use disorder. We estimated the annual prevalence of outpatient opioid prescriptions and incidence of opioid-related adverse events, defined as an emergency department visit, hospitalization, or death related to an opioid adverse effect. RESULTS: There were 1 362 503 outpatient opioid prescriptions; the annual mean prevalence of opioid prescriptions was 15.0%. The most common opioid indications were dental procedures (31.1% prescriptions), outpatient procedure and/or surgery (25.1%), trauma (18.1%), and infections (16.5%). There were 437 cases of opioid-related adverse events confirmed by medical record review; 88.6% were related to the child’s prescription and 71.2% had no recorded evidence of deviation from the prescribed regimen. The cumulative incidence of opioid-related adverse events was 38.3 of 100 000 prescriptions. Adverse events increased with age (incidence rate ratio = 2.22; 95% confidence interval, 1.67–2.96; 12–17 vs 2–5 years of age) and higher opioid doses (incidence rate ratio = 1.86 [1.45–2.39]; upper versus lower dose tertiles). CONCLUSIONS: Children without severe conditions enrolled in Tennessee Medicaid frequently filled outpatient opioid prescriptions for acute, self-limited conditions. One of every 2611 study opioid prescriptions was followed by an opioid-related adverse event (71.2% of which were related to therapeutic use of the prescribed opioid).

1 February 2012 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
CCCecilia Chung
Cecilia Chung
JGJon T. Giles
Jon T. Giles
MPMichelle Petri
Michelle Petri
MSMoyses Szklo
Moyses Szklo
WPWendy Post
Wendy Post
JBJoan M. Bathon
Joan M. Bathon

14 December 2006 in Arthritis Research & Therapy
Verified
Journal Article
Open access
CCCecilia Chung
Cecilia Chung
AOAnnette Oeser
Annette Oeser
IAIngrid Avalos
Ingrid Avalos
TGTebeb Gebretsadik
Tebeb Gebretsadik
ASAyumi Shintani
Ayumi Shintani
CSC Michael Stein
C Michael Stein
The prevalence of ischemic heart disease and atherosclerosis is increased in patients with rheumatoid arthritis (RA). In the general population, but not in patients with systemic lupus erythematosus, the Framingham risk score identifies patients at increased cardiovascular risk and helps determine the need for preventive interventions. We examined the hypothesis that the Framingham score is increased and associated with coronary-artery atherosclerosis in patients with RA. The Framingham score and the 10-year cardiovascular risk were compared among 155 patients with RA (89 with early disease, 66 with long-standing disease) and 85 control subjects. The presence of coronary-artery calcification was determined by electron-beam computed tomography. The Framingham score was compared in patients with RA and control subjects, and the association between the risk score and coronary-artery calcification was examined in patients. Patients with long-standing RA had a higher Framingham score (14 [11 to 18]) (median [interquartile range]) compared to patients with early RA (11 [8 to 14]) or control subjects (12 [7 to 14], P < 0.001). This remained significant after adjustment for age and gender (P = 0.015). Seventy-six patients with RA had coronary calcification; their Framingham risk score was higher (14 [12 to 17]) than that of 79 patients without calcification (10 [5 to 14]) (P < 0.001). Furthermore, a higher Framingham score was associated with a higher calcium score (odds ratio [OR] = 1.20, 95% confidence interval [CI] 1.12 to 1.29, P < 0.001), and the association remained significant after adjustment for age and gender (OR = 1.15, 95% CI 1.02 to 1.29, P = 0.03). In conclusion, a higher Framingham risk score is independently associated with the presence of coronary calcification in patients with RA.

1 April 2013 in Psychiatry Research
Verified
Journal Article
Closed access
CCCecilia Chung
Cecilia Chung
DSDennis Schmidt
Dennis Schmidt
CSCharles Michael Stein
Charles Michael Stein
JMJason D. Morrow
Jason D. Morrow
RSRonald M. Salomon
Ronald M. Salomon